Description
What is the use of Canakinumab Injection?
Canakinumab is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still’s disease, including adult-onset Still’s disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.
Has ILARIS (Canakinumab) been launched in India?
No, ILARIS (Canakinumab) Injection is not officially launched or commercially marketed for regular sale in India yet. To get access, give a request to Lucknow Speciality Pharma team.
Patient Access Facilitation for ILARIS (Canakinumab) Injection
ILARIS (Canakinumab) Injection is an unregistered/restricted drug in India. The Lucknow Speciality Pharma acts purely as a logistics and documentation facilitator to assist patients and hospitals in accessing ILARIS (Canakinumab) strictly for personal medical use under the Named Patient Program (NPP), in full compliance with the Drugs and Cosmetics Rules and guidelines set by the Central Drugs Standard Control Organisation (CDSCO).
To give request – contact sourcing facilitation team
Contact Name: Jitender Mishra
Company Name: Lucknow Speciality pharma
Address: 2nd Floor, 207-A, Felix Square, Golf City, Gomti Nagar, Lucknow, Uttar Pradesh 226030
Disclaimer:
ILARIS (Canakinumab) Injection is not commercially marketed or locally stocked for open retail distribution in India. Access is facilitated exclusively under the Named Patient Program (NPP) framework governed by the Central Drugs Standard Control Organisation (CDSCO) and Rule 36 of the Drugs & Cosmetics Rules. All imports require a valid prescription from a Registered Medical Practitioner, mandatory regulatory approvals, and are strictly for individual personal use. The Lucknow Speciality Pharma functions solely as a regulatory documentation and logistics facilitation service provider.
FAQ's
How to Access ILARIS in India?
Under the Named Patient Program (NPP), patients in India can legally import non-registered, life-saving medications like ILARIS (Canakinumab) Injection for personal medical use. This process is compliant with Rule 36 of the Drugs & Cosmetics Rules, 1945, and subject to approval from the Central Drugs Standard Control Organisation (CDSCO).
What is the role of Lucknow Speciality Pharma?
On request,
Lucknow Speciality Pharma assists patients, treating specialists, and hospitals by facilitating the legal sourcing and import process through authorized global pharmaceutical networks.
We assist with:
- Processing regulatory documentation and CDSCO import permit filings (Form 12A/12B).
- Coordinating customs clearance and end-to-end import formalities.
- Managing GDP-compliant, temperature-controlled cold-chain logistics for direct delivery to hospitals or individual patients.
How much do ILARIS (Canakinumab) Injection cost in Lucknow, India?
The cost of ILARIS is variable and may depend on factors such as the source of procurement, applicable duties and taxes, and import logistics. Accordingly, it is advisable to consult a specialized facilitator to obtain accurate and up-to-date pricing and availability details. To procure this medication legally, you can call at
9336559090 or WhatsApp at
9336559090 or email us at
info@lucknowpharma.com
Where does The Lucknow Speciality Pharma supply medicines and medical products?
The
Lucknow Speciality Pharma supports healthcare facilities, medical practitioners, and individual patients across 10 regional territories—including Uttar Pradesh, Uttarakhand, Haryana, Delhi (NCR), Rajasthan, Madhya Pradesh, Chhattisgarh, Bihar, Jharkhand, and Nepal.
Key Metropolitan & Regional Delivery Hubs:
- Delhi (NCR): Delhi, Gurugram, Noida, Greater Noida, Ghaziabad.
- Uttar Pradesh: Lucknow, Kanpur, Prayagraj, Varanasi, Agra, Meerut, Bareilly, Gorakhpur, Aligarh, Moradabad, Jhansi, Mathura–Vrindavan, Ayodhya, and surrounding districts.
- Eastern & Central India: Patna, Gaya, Bhagalpur, Muzaffarpur, Darbhanga (Bihar); Ranchi (Jharkhand); Bhopal, Indore (Madhya Pradesh); Raipur (Chhattisgarh); Jaipur (Rajasthan); Dehradun (Uttarakhand).
- Expanded Regional Coverage: Guwahati (Assam), Agartala (Tripura), Imphal (Manipur), Kolkata, Siliguri, Asansol (West Bengal), and Nepal.